Participant Perspectives and Experiences Entering an Intensively Monitored Antiretroviral Pause: Results from the AIDS Clinical Trials Group A5345 Biomarker Study.

HIV cure-related research analytical treatment interruption behavioral sciences intensively monitored antiretroviral pause persons living with HIV social sciences

Journal

AIDS research and human retroviruses
ISSN: 1931-8405
Titre abrégé: AIDS Res Hum Retroviruses
Pays: United States
ID NLM: 8709376

Informations de publication

Date de publication:
06 2021
Historique:
pubmed: 22 1 2021
medline: 19 8 2021
entrez: 21 1 2021
Statut: ppublish

Résumé

The AIDS Clinical Trials Group (ACTG) A5345 study included an intensively monitored antiretroviral pause (IMAP), during which a cohort of participants temporarily stopped antiretroviral treatment during chronic HIV infection. We surveyed participant perceptions and understanding of A5345 using a cross-sectional sociobehavioral questionnaire. Participants completed the baseline questionnaire either before or after initiating the study's IMAP. Questionnaire responses were linked to existing demographic data. Quantitative responses were analyzed overall and stratified by IMAP status. Open-ended responses were analyzed using conventional content analysis. Thirty-two participants completed the baseline sociobehavioral questionnaire. Half (

Identifiants

pubmed: 33472545
doi: 10.1089/AID.2020.0222
pmc: PMC8213012
doi:

Substances chimiques

Biomarkers 0

Banques de données

ClinicalTrials.gov
['NCT03001128']

Types de publication

Clinical Trial Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

489-501

Subventions

Organisme : NIMH NIH HHS
ID : R21 MH118120
Pays : United States
Organisme : NIAID NIH HHS
ID : U01 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068634
Pays : United States
Organisme : NIAID NIH HHS
ID : UM1 AI068636
Pays : United States

Références

J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S24-S26
pubmed: 31264691
IRB. 2018 Jul-Aug;40(4):8-12
pubmed: 30387975
J Int AIDS Soc. 2019 Mar;22(3):e25260
pubmed: 30869203
N Engl J Med. 2018 Feb 22;378(8):766-771
pubmed: 29466147
Br J Clin Psychol. 1983 Nov;22 (Pt 4):245-9
pubmed: 6640176
Epidemiology. 2017 Jul;28(4):553-561
pubmed: 28346267
AIDS Res Hum Retroviruses. 2018 Jan;34(1):67-79
pubmed: 28562069
PLoS Pathog. 2018 Jan 11;14(1):e1006792
pubmed: 29324842
AIDS Res Hum Retroviruses. 2020 Jul;36(7):606-615
pubmed: 32368934
AIDS. 2020 Jun 1;34(7):1095-1099
pubmed: 32287066
J Int AIDS Soc. 2020 Feb;23(2):e25453
pubmed: 32107887
Curr Opin HIV AIDS. 2018 Sep;13(5):422-427
pubmed: 30015634
AIDS Care. 2010 Nov;22(11):1403-9
pubmed: 20936540
AIDS Res Hum Retroviruses. 2020 Apr;36(4):268-282
pubmed: 32160755
Ethics Hum Res. 2019 May;41(3):13-22
pubmed: 31108576
PLoS One. 2017 Nov 2;12(11):e0187489
pubmed: 29095883
J Pediatr. 1999 Feb;134(2):130-1
pubmed: 9931513
J Virus Erad. 2015 Jan 01;1(1):43-8
pubmed: 27482394
J Infect Dis. 2019 Jul 2;220(220 Suppl 1):S5-S6
pubmed: 30779842
Trends Microbiol. 2014 Oct;22(10):547-9
pubmed: 25280965
Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
AIDS Res Hum Retroviruses. 2019 Jan;35(1):100-107
pubmed: 30009625
Health Qual Life Outcomes. 2012 Nov 01;10:132
pubmed: 23116130
Arthritis Care Res (Hoboken). 2011 Nov;63 Suppl 11:S467-72
pubmed: 22588767
AIDS Care. 2018 Jul;30(7):914-920
pubmed: 29347826
Trends Microbiol. 2016 Jan;24(1):5-11
pubmed: 26642901
J Virus Erad. 2020 Feb 20;6(1):34-37
pubmed: 32175090
J Int AIDS Soc. 2020 Feb;23(2):e25443
pubmed: 32077248
AIDS. 2019 Apr 1;33(5):773-791
pubmed: 30883388
Nat Immunol. 2013 Nov;14(11):1104-7
pubmed: 24145780
Lancet HIV. 2016 Oct;3(10):e456-7
pubmed: 27687034
J Int AIDS Soc. 2019 Oct;22(10):e25404
pubmed: 31665568
J Antimicrob Chemother. 2020 May 1;75(5):1311-1320
pubmed: 32053203
J Med Ethics. 2018 Apr;44(4):270-276
pubmed: 29127137
J Empir Res Hum Res Ethics. 2018 Feb;13(1):3-17
pubmed: 28984168
Lancet HIV. 2019 Apr;6(4):e259-e268
pubmed: 30885693
Clin Infect Dis. 2020 Mar 17;70(7):1418-1420
pubmed: 31102443
PLoS One. 2017 Jan 25;12(1):e0170112
pubmed: 28122027
Lancet HIV. 2019 Mar;6(3):e147-e149
pubmed: 30772419
J Virus Erad. 2017 Apr 1;3(2):82-84
pubmed: 28435691
AIDS Res Hum Retroviruses. 2015 Jan;31(1):56-63
pubmed: 25406579
J Virus Erad. 2019 Sep 18;5(3):152-162
pubmed: 31700661
Clin Infect Dis. 2020 Mar 17;70(7):1406-1417
pubmed: 31102444
Nat Rev Immunol. 2012 Jul 20;12(8):607-14
pubmed: 22814509
Curr Opin HIV AIDS. 2018 Sep;13(5):416-421
pubmed: 29878912

Auteurs

Karen L Diepstra (KL)

UNC Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.

Liz Barr (L)

AIDS Clinical Trials Group (ACTG) Community Scientific Sub-Committee, Baltimore, Maryland, USA.

David Palm (D)

Institute of Global Health and Infectious Diseases (IGHID), University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Evelyn Hogg (E)

Social & Scientific Systems, a DLH Company, Silver Spring, Maryland, USA.

Katie R Mollan (KR)

Center for AIDS Research (CFAR), School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Laney Henley (L)

UNC Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.

Angela M Stover (AM)

UNC Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.

Jane M Simoni (JM)

Department of Psychology, University of Washington, Seattle, Washington, USA.
Department of Global Health and Gender, Women, and Sexuality Studies, University of Washington, Seattle, Washington, USA.

Jeremy Sugarman (J)

Johns Hopkins Berman Institute for Bioethics, Baltimore, Maryland, USA.

Brandon Brown (B)

Department of Social Medicine, Population and Public Health, Center for Healthy Communities, University of California, Riverside School of Medicine, Riverside, California, USA.

John A Sauceda (JA)

Division of Prevention Sciences, Center for AIDS Prevention Studies (CAPS), University of California, San Francisco, San Francisco, California, USA.

Steven Deeks (S)

Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, San Francisco, California, USA.

Lawrence Fox (L)

National Institute of Health (NIH) Division of AIDS (DAIDS), Bethesda, Maryland, USA.

Rajesh T Gandhi (RT)

Massachusetts General Hospital, Boston, Massachusetts, USA.

Davey Smith (D)

Division of Infectious Diseases and Global Health, University of California, San Diego, California, USA.

Jonathan Z Li (JZ)

Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Karine Dubé (K)

UNC Gillings School of Global Public Health, Chapel Hill, North Carolina, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH